The only conclusion that we could make was that people treated with minocycline for acne are at a significantly greater risk of developing an autoimmune (lupus‐like) syndrome than those given tetracycline or no treatment.Īntineutrophil antibodies are a group of autoantibodies. Although it is often claimed that the more expensive once‐daily slow‐release preparation is a more attractive option to teenagers with acne, the evidence in this review does not show it to be any better or safer compared to other oral antibiotics that have to be taken more frequently.ĭespite a thorough search for evidence, it is still not known which of the tetracyclines are the safest to take overall as they are all associated with side‐effects.
There is no evidence that it is more effective in acne that is resistant to other therapies, or that the effects last longer. The analysis found that minocycline may act more quickly than oxytetracycline or tetracycline, but there is no overall difference in the end. However, no study conclusively showed any important clinical difference between minocycline or other commonly‐used therapies. All of the trials showed that, on average, people treated with minocycline experienced an improvement in their acne. In summary, there is no evidence to support the first‐line use of minocycline in the treatment of acne. Twelve new RCTs were identified, making a total of 39 RCTs (6013 participants).
DIANE 35 ACNÉ RÉSULTATS UPDATE
This update was undertaken to identify whether there was any new evidence that might change the conclusions of the original review or provide information on risks associated with minocycline therapy. In the UK, the daily cost of generic minocycline is now one third the cost of tetracycline. Since the first version of this review, minocycline's cost has fallen. It was also more expensive than other treatments.
DIANE 35 ACNÉ RÉSULTATS SKIN
Over recent years it has been used less, which was due to serious concerns about its safety, including skin pigmentation, which in some cases is irreversible. Minocycline was the most prescribed antibiotic used to treat acne because it was thought to be better than other options, despite the original version of this review finding no reliable evidence that it was any better than other treatments. There are many different treatment options, but there is little good evidence to inform doctors and individuals about which to choose. However, in some people it persists in to adulthood. Minocycline for acne vulgaris: efficacy and safetyĪcne is the most common skin disease of adolescence, and in most cases it clears spontaneously. The evidence does not support the conclusion that the more expensive extended‐release preparation is safer than standard minocycline preparations.
The risk of autoimmune reactions increases with duration of use. Minocycline, but not other tetracyclines, is associated with lupus erythematosus, but the risk is small: 8.8 cases per 100,000 person‐years. The evidence suggests that minocycline is associated with more severe adverse effects than doxycycline. The adverse effects studies must be interpreted with caution. Also, there is no evidence to guide what dose should be used. No trials have been conducted using minocycline in those participants whose acne is resistant to other therapies. One company‐sponsored RCT found minocycline to be less effective than combination treatment with topical erythromycin and zinc. Although minocycline was shown to be an effective treatment for moderate to moderately‐severe acne vulgaris, there was no evidence that it is better than any of the other commonly‐used acne treatments.
DIANE 35 ACNÉ RÉSULTATS TRIAL
Meta‐analysis was rarely possible because of the lack of data and different outcome measures and trial durations. The identified RCTs were generally small and poor quality. These additional 12 RCTs have not changed the original conclusions about the clinical efficacy of minocycline. We included 12 new RCTs for this update, giving a total of 39 RCTs (6013 participants).